乳腺癌新辅助治疗中外指南对比解读  

Interpretation of Chinese and foreign guidelines for neoadjuvant treatment of breast cancer

作　　者：陈伟玲 张国君 CHEN Weiling;ZHANG Guojun(Department of Breast Thyroid Surgery,Xiang an Hospital of Xiamen University,Xiamen 361101,China;Cancer Center,Medical College of Xiamen University,Xiamen 361105,China)

机构地区：[1]厦门大学附属翔安医院乳腺甲状腺外科,福建厦门361101 [2]厦门大学医学院癌症中心,福建厦门361005

出　　处：《中国肿瘤外科杂志》2023年第3期219-224,共6页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金(32171363);福建省科技重大专项(2020YZ016002)。

摘　　要：新辅助治疗已成为乳腺癌综合治疗中重要的组成部分。随着最新临床试验结果的不断涌现和乳腺癌治疗理念的更新,乳腺癌新辅助治疗已由单一化的化疗模式转变为以乳腺癌分子分型为基础的新辅助化疗、新辅助内分泌治疗、新辅助靶向治疗[抗人表皮生长因子受体2 (HER2)]联合化疗等个体精准化模式。作者围绕乳腺癌新辅助治疗策略等要点难点问题、对照乳腺癌中外指南及专家共识,逐一解读,总结出客观具体切实可行的推荐意见。Neoadjuvant therapy has become an important part of the comprehensive treatment of breast cancer.With the emergence of the latest clinical trial results and the update of the treatment concept of breast cancer,the neoadjuvant treatment of breast cancer has been changed from a single chemotherapy mode to an individualized precise mode based on the molecular classification of breast cancer,such as neoadjuvant chemotherapy,neoadjuvant endocrine therapy,neoadjuvant targeted therapy combined with chemotherapy.The authors focused on the key and difficult issues such as the neoadjuvant therapy strategy of breast cancer,interpretation of Chinese and foreign guidelines,and expert consensus on breast cancer,and summarized the objective,specific and practical recommendations for clinical treatment decisions.

关 键 词：乳腺癌 新辅助治疗 指南 共识 解读 

分 类 号：R737.9[医药卫生—肿瘤]